Using a single tablet regimen of darunavir, cobicistat, emcitrabine, and tenofovir alafenamide in virally suppressed HIV-1 patients is an adequate treatment option for controlling HIV

Clinical Research in Practice The Journal of Team Hippocrates ◽

10.22237/crp/1625097720 ◽

2021 ◽

Vol 7 (2) ◽

Author(s):

Priya Kathuria

Keyword(s):

Protease Inhibitors ◽

Treatment Option ◽

Tenofovir Disoproxil Fumarate ◽

Clinical Decision ◽

Efficacy And Safety ◽

Phase 3 ◽

Adequate Treatment ◽

Single Tablet Regimen ◽

Tenofovir Alafenamide ◽

A clinical decision report using: Orkin C, Molina JM, Negredo E, et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018;5(1):e23-e34. https://doi.org/10.1016/S2352-3018(17)30179-0 for a patient with viriologically suppressed HIV-1.

Download Full-text

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

Antiviral Research ◽

10.1016/j.antiviral.2019.104543 ◽

2019 ◽

Vol 170 ◽

pp. 104543 ◽

Author(s):

Joseph J. Eron ◽

Chloe Orkin ◽

Douglas Cunningham ◽

Federico Pulido ◽

Frank A. Post ◽

...

Keyword(s):

Protease Inhibitors ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Single Tablet Regimen ◽

Tenofovir Alafenamide ◽

Living With Hiv ◽

Download Full-text

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

The Lancet HIV ◽

10.1016/s2352-3018(17)30179-0 ◽

2018 ◽

Vol 5 (1) ◽

pp. e23-e34 ◽

Author(s):

Chloe Orkin ◽

Jean-Michel Molina ◽

Eugenia Negredo ◽

José R Arribas ◽

Joseph Gathe ◽

...

Keyword(s):

Protease Inhibitors ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Download Full-text

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

The Lancet HIV ◽

10.1016/s2352-3018(16)00024-2 ◽

2016 ◽

Vol 3 (4) ◽

pp. e158-e165 ◽

Author(s):

Joel E Gallant ◽

Eric S Daar ◽

François Raffi ◽

Cynthia Brinson ◽

Peter Ruane ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

HIV Research & Clinical Practice ◽

10.1080/25787489.2020.1844520 ◽

2020 ◽

Vol 21 (6) ◽

pp. 151-167

Author(s):

Gregory D. Huhn ◽

Aimee Wilkin ◽

Cristina Mussini ◽

Christoph D. Spinner ◽

John Jezorwski ◽

...

Keyword(s):

Antiretroviral Treatment ◽

Efficacy And Safety ◽

Phase 3 ◽

Single Tablet Regimen ◽

Subgroup Analyses ◽

Tenofovir Alafenamide ◽

Living With Hiv ◽

Download Full-text

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial

HIV Clinical Trials ◽

10.1080/15284336.2017.1291867 ◽

2017 ◽

Vol 18 (3) ◽

pp. 135-140 ◽

Author(s):

Frank A. Post ◽

Yazdan Yazdanpanah ◽

Gabriel Schembri ◽

Adriano Lazzarin ◽

Jacques Reynes ◽

...

Keyword(s):

Subgroup Analysis ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Tenofovir Alafenamide ◽

Download Full-text

Longer-Term Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide Versus Emtricitabine and Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Week 96 Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3772801 ◽

2021 ◽

Author(s):

Onyema Ogbuagu ◽

Peter J. Ruane ◽

Daniel Podzamczer ◽

Laura C. Salazar ◽

Keith Henry ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Tenofovir Alafenamide ◽

Exposure Prophylaxis ◽

Download Full-text

IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

10.1136/gutjnl-2019-iddfabstracts.278 ◽

2019 ◽

Author(s):

Henry Lik Yuen Chan ◽

Pietro Lampertico ◽

Maria Buti ◽

Scott Fung ◽

Sang Hoon Ahn ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide

Download Full-text

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)00348-5 ◽

2016 ◽

Vol 16 (1) ◽

pp. 43-52 ◽

Author(s):

Anthony Mills ◽

Jose R Arribas ◽

Jaime Andrade-Villanueva ◽

Giovanni DiPerri ◽

Jan Van Lunzen ◽

...

Keyword(s):

Tenofovir Disoproxil Fumarate ◽

Phase 3 ◽

Open Label Phase ◽

Tenofovir Alafenamide ◽

Download Full-text

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study

Gastroenterology ◽

10.1016/s0016-5085(17)33661-2 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1086

Author(s):

Maurizia Rossana Brunetto ◽

Young-Suk Lim ◽

Edward Gane ◽

Wai-Kay Seto ◽

Marina Osipenko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Negative Chronic Hepatitis

Download Full-text

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Gastroenterology ◽

10.1016/s0016-5085(17)33660-0 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1085-S1086

Author(s):

Kosh Agarwal ◽

Scott Fung ◽

Wai-Kay Seto ◽

Young-Suk Lim ◽

Edward Gane ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide

Download Full-text